Business
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
Trial to resolve all claims in the Anaptys and Tesaro/GSK dispute is scheduled for July 14-17, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, filed a partial motion to dismiss Tesaro’s anticipatory breach of contract claim in Delaware Chancery Court related to pending litigation between Anaptys, GSK, and TESARO, Inc. (“Tesaro”) regarding their Collaboration and Exc
About this update from Anaptysbio, Inc.
[{"type":"image","alt":"AnaptysBio, Inc.","displaySize":"","headline":null,"caption":"AnaptysBio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/5dd7f30a0ad6f5e52c819b2cf00b5a83"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zHX60hU6t6UlKPA8Q7HKXQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5dd7f30a0ad6f5e52c819b2cf00b5a83","width":300,"height":85}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Trial to resolve all claims in the Anaptys and Tesaro/GSK dispute is scheduled for July 14-17, 2026","length":99,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":99,"olType":false},{"type":"text","content":"SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, filed a partial motion to dismiss Tesaro’s anticipatory breach of contract claim in Delaware Chancery Court related to pending litigation between Anaptys, GSK, and TESARO, Inc. (“Tesaro”) regarding their Collaboration and Exclusive License Agreement (“Collaboration Agreement”), which entitles Anaptys to receive royalties upon sales of Jemperli.","length":521,"tagName":"p"},{"type":"text","content":"As previously disclosed, Anaptys approached Tesaro to engage in good faith discussions to potentially resolve Anaptys’ claims that Tesaro and GSK had breached the Collaboration Agreement. On Nov. 20, 2025, Tesaro, without notice to Anaptys and with discussions ongoing, initiated a lawsuit against Anaptys, claiming that Anaptys had repudiated the Collaboration Agreement and seeking a declaration that Tesaro had not breached.","length":427,"tagName":"p"},{"type":"text","content":"In response, Anaptys filed its own Complaint in Delaware Chancery Court, requesting a court declaration that Tesaro has materially breached the parties’ Collaboration Agreement and that GSK, Tesaro’s corporate parent, has tortiously interfered with the Collaboration Agreement.","length":277,"tagName":"p"},{"type":"text","content":"Further, on Dec. 30, 2025, Anaptys filed a Motion to Dismiss Tesaro’s anticipatory breach of contract claim in the same court. The motion, unsealed on Jan. 8, 2026, explains why, as a matter of law, Anap...